Skip to main content

Benevich Eric's Form 4/A amendment

Amended

Neurocrine Biosciences Inc (NBIX) · filed Jan 16, 2026

Accession no.
0001643653-26-000005
Filed
Jan 16, 2026
Trade date
Nov 28, 2025
Filing delay
49 days
Rule 10b5-1 plan
Not checked
Original filed
Dec 2, 2025

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $905.9K. It was filed 49 days after the trade.

This amendment replaces 0001643653-25-000007 (filed Dec 2, 2025).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Benevich EricCIK 0001643653Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 28, 2025Common StockSSaleDisposed−5,970$151.74−$905,887.844,893Direct
Nov 28, 2025Common StockMOption exerciseAcquired+12,830$35.99+$461,751.757,723Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 28, 2025Common StockMOption exerciseDisposed−12,830$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)